Initial assessment
Assessment begins with reproductive history, physical examination and at least one semen analysis.
Male infertility requires assessment of factors related to sperm production and transport, ejaculation, hormones, genetics and overall health.

Semen parameters can vary naturally. Medical history, examination, repeat analysis, hormone results and genetic assessment when indicated should be interpreted together.
Assessment begins with reproductive history, physical examination and at least one semen analysis.
Varicocele, hormonal disorders, obstruction, genetic factors, infection, medication and lifestyle factors are considered.
Depending on the cause, monitoring, medical treatment, surgery, IUI, IVF, ICSI or sperm-retrieval procedures may be considered.
Male-factor findings are considered together with the female partner’s age, ovarian reserve and pregnancy goals.
Male infertility is a broad term for sperm, hormonal, anatomical or genetic factors that reduce the chance of conception.
Male infertility is not simply a low sperm count. Sperm motility and morphology, sperm production, reproductive-tract patency, ejaculation, hormones, genetic factors and general health are assessed together.
Difficulty conceiving should not automatically be attributed to one partner. Assessing both partners in parallel can reduce unnecessary delay and help select the appropriate treatment pathway.
Semen analysis is an important first-line test, but no single parameter can reliably predict natural conception on its own. Multiple significant abnormalities together may be clinically important.
Male infertility can sometimes be the first indication of a broader health issue. Hormonal disorders, genetic conditions, testicular disease and some systemic illnesses may be identified during assessment.

Semen analysis is a laboratory test; male infertility is a broader clinical field that may require medical assessment and treatment.
History, examination, semen analysis, hormone tests, genetics and imaging are considered together.
It reports semen volume, sperm concentration/count, motility, morphology and other characteristics of the ejaculate.
The spermatogenic cycle, febrile illness, medication, sample-collection conditions and natural biological variation can affect results.
Assessment of the male partner is a core part of fertility evaluation for couples trying to conceive.
If pregnancy has not occurred despite regular unprotected intercourse, both partners should be assessed together.
Further assessment may be planned when there are significant abnormalities in sperm concentration/count, motility, morphology, semen volume or vitality.
Male-factor findings may be reassessed after unsuccessful IUI, IVF or ICSI treatment.
Karyotype testing and assessment of sperm DNA damage may be considered in selected couples.
Fertility preservation should be considered before chemotherapy, radiotherapy or testicular surgery when relevant.
Erectile dysfunction, inability to ejaculate or retrograde ejaculation can affect fertility planning.
No. Mild isolated abnormalities should be interpreted in the context of clinical history and the female partner’s fertility status, avoiding unnecessary supplements or procedures.
Tests should be selected step by step according to clinical findings rather than ordered as the same package for everyone.
Using a sample analysed according to WHO laboratory standards, semen volume, sperm concentration, total sperm count, motility and morphology are assessed.
FSH, LH and total testosterone may be requested particularly in oligozoospermia, azoospermia or when hormonal abnormalities are suspected.
Testicular volume, epididymis, vas deferens, varicocele and secondary sexual characteristics are assessed.
In azoospermia and severe oligozoospermia, karyotype testing, Y-chromosome microdeletion testing and CFTR assessment in appropriate cases may be considered.
Scrotal or transrectal ultrasound may be used in selected cases where anatomical abnormalities or obstruction are suspected.
Age, ovarian reserve and tubal status can influence treatment timing and the choice between IUI and IVF.
The aim is not simply to change semen parameters, but to identify the safest and most appropriate route to pregnancy for the couple.
Duration of infertility, pregnancy history, operations, medication, febrile illness and lifestyle factors are reviewed.
The sample is assessed under standard conditions and repeat testing may be planned if results are abnormal.
Physical examination, hormone results and imaging findings are interpreted together.
Impaired sperm production, obstruction, hormonal, genetic, infectious and unexplained causes are differentiated.
In appropriate cases, varicocele, hormonal abnormalities, medication effects, infection or lifestyle factors may be addressed.
Expectant management, IUI, IVF or ICSI may be considered according to total motile sperm count and the female partner’s fertility assessment.
In azoospermia, sperm retrieval from the epididymis or testis may be considered according to the underlying cause.
The plan is updated according to treatment response and the couple’s reproductive timeline.
Initial assessment can often be completed quickly, although hormone testing, genetic tests or surgical planning may extend the timeline.
Medical history and available test results can often be reviewed on the same day.
The semen sample is usually assessed on the same day, with reporting time depending on laboratory workflow.
A second sample may be requested after an appropriate interval when initial results are abnormal.
Hormone results are often available relatively quickly, while genetic testing may take longer.
A combined treatment roadmap is prepared once the relevant results for both partners are available.
Because spermatogenesis takes time, the effect of some medical or lifestyle interventions may only be assessed after several months.
A short visit may be sufficient for examination and semen analysis alone. If surgical sperm retrieval or coordinated IVF is planned, the required stay is individualised.
Outcomes depend not only on sperm count but also on the underlying cause and the couple’s overall reproductive potential.
Treatment options differ for obstruction, hormonal disorders, impaired sperm production and genetic causes.
These influence how long treatment can reasonably be delayed and the choice between IUI and IVF.
Total motile sperm count, morphology and vitality help guide treatment selection.
These may influence the likelihood of sperm retrieval and counselling about inherited risks to a future child.
Sample processing, identity verification, ICSI and cryopreservation procedures are important parts of laboratory care.
Smoking, obesity, fever, heat exposure, some medicines and systemic illnesses may affect sperm production.
Improvement in semen parameters, fertilisation, embryo development, clinical pregnancy and live birth are different outcomes and should be considered separately.
Rather than a fixed package, the necessary diagnostic and treatment steps should be explained individually.
Initial and, when required, repeat semen analysis.
FSH, LH, testosterone, ultrasound and selected additional tests.
Karyotype, Y-chromosome microdeletion, CFTR testing or genetic counselling when indicated.
Medication and follow-up appropriate to the identified cause.
Possible varicocele surgery, reconstruction, TESE or Micro-TESE.
ICSI, sperm freezing, cryostorage and any additional laboratory procedures.
Share your semen analyses, hormone results and previous treatment records so a plan can be prepared around the steps that are genuinely required.
Every stage from semen collection through sperm preparation, freezing and use in ICSI should be managed within a documented identity and traceability chain.
Sample acceptance, liquefaction, sperm concentration/count, motility and morphology are assessed using standard laboratory methods.
The patient, collection container, laboratory tubes and procedure records are linked through identity checks.
Washing, density-gradient preparation, swim-up or selected microfluidic methods may be used according to laboratory needs.
Limited or surgically retrieved sperm is stored with a separate identity and documented cryostorage location.
Viable sperm intended for fertilisation are assessed by the embryologist.
Equipment, incubators, microscopes and environmental conditions are monitored regularly.

Male-factor findings, the female partner’s treatment plan and embryology laboratory decisions are coordinated within the same care pathway.

Considers the female partner’s ovarian reserve and treatment timing together with the male-factor assessment.
View profile →
Coordinates diagnosis, treatment, consent and multidisciplinary planning for the couple.
View profile →
Manages semen analysis, sperm preparation, laboratory assessment of surgically retrieved samples, ICSI and cryopreservation steps.
View profile →Male examination, varicocele and surgical procedures such as TESE or Micro-TESE should be assessed by an appropriate urology or andrology specialist.
Expectations should be realistic and based on the identified cause, while unnecessary tests or routine add-on techniques should be avoided.
In some men, no definitive cause is found despite comprehensive assessment.
A single test can create false reassurance or unnecessary concern.
Not every antioxidant or supplement has been shown to improve pregnancy or live-birth outcomes.
TESE or Micro-TESE does not guarantee that sperm will be found.
Some male-factor genetic abnormalities may be inherited by a male child.
Prolonged male-only treatment may not be appropriate if female-partner age and ovarian reserve are not taken into account.
These answers provide general information; individual diagnosis requires semen analysis, clinical assessment and evaluation of both partners.
It refers to reduced reproductive potential related to sperm production, motility, morphology, transport, ejaculation, hormonal factors or genetic causes.
Semen analysis is the main initial test, but results should be interpreted together with medical history, examination and, when indicated, hormone, genetic and ultrasound findings.
A normal result may be sufficient in some situations, while an abnormal result may need to be repeated because of natural biological variability.
Depending on the cause, options may include hormonal treatment, surgery, lifestyle modification, IUI, IVF, ICSI or surgical sperm retrieval.
No. The decision depends on clinical examination, semen results, pain, testicular findings and the couple’s fertility plan.
Not necessarily. Total motile sperm count, other semen parameters and the female partner’s fertility status help determine treatment options.
An abnormal morphology result does not by itself mean infertility; it is interpreted together with sperm concentration, motility and clinical history.
Exogenous testosterone can suppress sperm production. Men wishing to conceive should not use testosterone without specialist medical advice.
Sperm DNA integrity and some reproductive outcomes may change with age, although the degree of effect varies between individuals.
Smoking and some lifestyle factors may adversely affect semen quality; stopping smoking is also important for general health.
No. Expectant management or IUI may be suitable in milder cases, while IVF with ICSI may be considered for more severe male-factor infertility.
Initial consultation and semen analysis can often be completed quickly, while genetic testing or surgical planning may take longer.